Core Viewpoint - The National Medical Insurance Administration has launched a campaign to combat the illegal sale and circulation of counterfeit drugs, emphasizing the importance of drug traceability to ensure public health and safety [1][2]. Group 1: Drug Traceability and Regulation - The campaign showcases the effectiveness of "code-based supervision" in tackling the issue of counterfeit drugs, which are often sourced through illegal channels and pose significant health risks to patients [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for tracking of drug sources and destinations [1]. Group 2: Challenges and Responsibilities - Despite the regulatory efforts, some illegal actors continue to profit from the distribution of non-compliant drugs, indicating that a comprehensive approach is necessary to eliminate the entire chain of illegal activities [2]. - Pharmaceutical companies, medical institutions, and retail pharmacies must adhere to strict drug sales management to prevent drugs from entering non-regulated channels, while the public should be aware of the risks and refrain from participating in the illegal sale of medical insurance drugs [2].

Core Viewpoint - The article emphasizes the importance of combating the illegal trade of "recycled drugs" to ensure public health and safety, highlighting the government's commitment to innovative regulatory measures to trace drug origins and prevent fraud [1][2]. Group 1: Regulatory Measures - The National Medical Insurance Administration has launched a special action to combat the illegal sale of recycled drugs, showcasing the effectiveness of "code-based supervision" [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for traceable drug origins and destinations [1]. Group 2: Risks of Recycled Drugs - Recycled drugs are often sourced through illegal channels, repackaged, or have their information altered, posing significant health risks to patients and disrupting market order [1]. - The methods used by drug traffickers include enticing insured individuals to sell insurance-covered drugs for profit, falsifying documents to disguise the origins of drugs, and neglecting proper storage conditions during the repackaging process [1]. Group 3: Collaborative Efforts - It is essential for pharmaceutical companies, medical institutions, and retail pharmacies to strictly manage drug sales and prevent drugs from entering informal channels [2]. - Public awareness and responsibility are crucial in preventing participation in the illegal trade of insurance-covered drugs, emphasizing that drug safety is a collective responsibility [2].

Core Viewpoint - The article highlights the rampant issues in online pharmaceutical sales, including counterfeit products, misleading labeling, and fraudulent reviews, which pose significant risks to consumers' safety and trust in e-commerce platforms [1][2][4]. Group 1: Counterfeit and Misleading Products - Numerous counterfeit products flood e-commerce platforms, often mimicking legitimate medications with similar packaging and names, leading to consumer confusion [1][2]. - Common tactics include "word games" where product names are altered to include terms like "repair" or "skin," and using similar color schemes to deceive consumers [2][4]. - Products labeled with "消字号" (disinfection) or "械字号" (medical device) are often misrepresented as effective medications, despite lacking rigorous clinical testing [4]. Group 2: Consumer Confusion and Regulatory Gaps - Consumers are often unfamiliar with the different product classifications, such as "国药准字" (national drug approval), which is the only legitimate identifier for approved medications [4]. - The approval process for non-drug products is less stringent, allowing potentially unsafe items to enter the market without adequate oversight [4]. Group 3: Fraudulent Practices on E-commerce Platforms - E-commerce sellers frequently engage in practices like fake reviews and inflated sales figures to mislead consumers into purchasing counterfeit products [6]. - The lack of a return policy for legitimate medications complicates consumer efforts to identify counterfeit products, as those that allow returns are likely not approved drugs [6]. Group 4: Regulatory Responses and Future Directions - The National Medical Insurance Administration is set to enhance drug traceability regulations starting January 1, 2025, aiming to create a comprehensive tracking system for pharmaceuticals [7]. - Experts emphasize the need for refined regulations to address the challenges posed by online drug sales, urging consumers to recognize legitimate products and utilize official tracking tools [8].

Group 1 - The National Healthcare Security Administration (NHSA) has made significant progress in addressing issues related to the management of medical insurance funds, particularly in combating illegal activities such as the resale of "returned drugs" [1] - "Returned drugs" refer to pharmaceuticals that have exited the legitimate distribution channels and re-entered the market, often through illegal means, posing risks to public health and safety [1] - The NHSA has launched a drug traceability information query function on its platform, allowing pharmacies to identify "returned drugs" through scanning, thereby ensuring the legality of drug sources [1][2] Group 2 - As of now, the NHSA has collected a total of 39.885 billion drug traceability codes to assist in combating the "returned drug" issue [2] - The NHSA plans to enhance the regulatory application of drug traceability codes, focusing on building a big data regulatory model to combat illegal drug trading and other violations [2] - The NHSA has initiated a special action to combat the production and sale of counterfeit and inferior drugs, with the first phase of verification tasks completed and several cases of "returned drugs" being addressed [2]